Inhibition of the mutated c-KIT kinase in AML1-ETO–positive leukemia cells restores sensitivity to PARP inhibitor Journal Article

   

Authors:	Nieborowska-Skorska, M.; Paietta, E. M.; Levine, R. L.; Fernandez, H. F.; Tallman, M. S.; Litzow, M. R.; Skorski, T.
Article Title:	Inhibition of the mutated c-KIT kinase in AML1-ETO–positive leukemia cells restores sensitivity to PARP inhibitor
Keywords:	clinical article; controlled study; gene mutation; human cell; doxorubicin; drug efficacy; protein tyrosine kinase; cancer inhibition; drug mechanism; leukemia cell; drug response; western blotting; clonogenic assay; drug sensitivity; cd34 selection; cell activity; olaparib; transcription factor runx1; core binding factor; acute myeloid leukemia; human; priority journal; article; avapritinib; protein cbfa2t1
Journal Title:	Blood Advances
Volume:	3
Issue:	23
ISSN:	2473-9529
Publisher:	American Society of Hematology
Date Published:	2019-12-10
Start Page:	4050
End Page:	4054
Language:	English
DOI:	10.1182/bloodadvances.2019000756
PUBMED:	31816060
PROVIDER:	scopus
PMCID:	PMC6963253
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85076356933&doi=10.1182%2fbloodadvances.2019000756&partnerID=40&md5=e8599bb90b79b0e5b76ba158c7289ab7
Notes:	Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/157539